-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.
-
Summary
-
Elite Pharmaceuticals Inc /Nv/ quarterly/annual Current Income Tax Expense (Benefit) history and growth rate from Q2 2023 to Q4 2024.
- Elite Pharmaceuticals Inc /Nv/ Current Income Tax Expense (Benefit) for the quarter ending December 31, 2024 was -$239K, a 130% decline year-over-year.
- Elite Pharmaceuticals Inc /Nv/ Current Income Tax Expense (Benefit) for the twelve months ending December 31, 2024 was -$19.8M.
- Elite Pharmaceuticals Inc /Nv/ annual Current Income Tax Expense (Benefit) for 2023 was $343K, a 19.1% decline from 2022.
Current Income Tax Expense (Benefit), Trailing 12 Months (USD)
Current Income Tax Expense (Benefit), Quarterly (USD)
Current Income Tax Expense (Benefit), YoY Quarterly Growth (%)